Conjugated meningococcal ACWY-TT (vaccine)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Meningococcal

Phase 2

Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine

CompletedNCT00126984

GlaxoSmithKlineInfections, Meningococcal

Start: 2005-07-31End: 2008-02-29Updated: 2016-10-07

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

CompletedNCT00196976

GlaxoSmithKlineInfections, Meningococcal

Start: 2005-03-24End: 2006-03-03Updated: 2018-06-08

Related Papers

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.

2012-04-0920 citations